Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu
CEO and MD, Dr Oludare Odumosu
Source: Zelira Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zelira Therapeutics (ZLD) launches its first product line, RAF FIVE, through its dermatology subsidiary, Ilera Derm LLC
  • The product line includes a mix of acne treatment and sunscreen, and known skin-boosting ingredients such as peptides and hyaluronic acid
  • RAF FIVE is now available in the US and the launch marks Zelira’s first step into the acne medication market
  • After 30 days of using the product, 92 per cent of users reported smoother skin while 90 per cent indicated blemishes cleared up more quickly
  • Zelira is up 10.5 per cent on the market with shares trading at 4.2 cents at 12:58 pm AEST

Zelira Therapeutics (ZLD) has launched its first product line, RAF FIVE, through its dermatology subsidiary, Ilera Derm LLC.

The RAF FIVE product line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, Clear the Way Acne Treatment Pads and After Hours Moisturising Lotion Acne Treatment.

These products are known to include skin-boosting ingredients such as glycerin, hyaluronic acid, peptides, thiotaine and niacinamide.

The launch of RAF FIVE is Zelira’s first step into the acne medication market, which is worth more than US$11 billion (A$15.1 billion) worldwide.

RAF FIVE is now available in the US and is the only skincare line to feature Zylorma which is an acne-fighting complex developed by Zelira and US board-certified cosmetic dermatologist Karyn Grossman.

Zylorma uses a proprietary CBD formulation with salicylic acid and botanical compounds to fight bacteria and clogged pores associated with acne.

Dr Grossman commented on the partnership.

“I am thrilled to be a part of the new Ilera Derm and to have teamed up with Zelira to create Zylorma and the RAF FIVE skincare line,” Dr Grossman said.

“I believe that science has just started to skim the surface of the skin-healing properties of cannabinoids; RAF FIVE is only the beginning.”

After a week of using the RAF FIVE products, 92 per cent of participants saw blemishes improve, 97 reported less inflamed blemishes and 90 per cent saw blemishes significantly reduce in size.

After two weeks, 97 per cent reported smoother skin, 95 per cent saw a more even skin tone and 92 per cent said blemishes reduced in frequency.

After 30 days, 92 per cent reported smoother skin, 90 per cent indicated blemishes cleared up quicker and 92 per cent reported blemishes were flatter and less inflamed.

Zelira CEO and Managing Director Oludare Odumosu is excited about the launch.

“I am excited to announce the launch of Zelira’s dermatology subsidiary and the RAF FIVE acne treatment line of skincare products,” Dr Odumosu commented.

“We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the US$11 billion acne treatment market, where there is a high level of dissatisfaction with existing products and unmet needs.”

Zelira’s subsidiary is currently in the process of developing several other products, such as anti-aging, sexual health and intimacy, and skin conditions, with launch expected in 2022.

Zelira is up 10.5 per cent on the market with shares trading at 4.2 cents at 12:58 pm AEST.

ZLD by the numbers
More From The Market Herald

" Resonance Health (ASX:RHT) contracted for third party liver disease study

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for a clinical study to…

" Cann Group (ASX:CAN) granted GMP licence by TGA

Cann Group (ASX:CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic…
1st Group (ASX:1ST) - Managing Director, Klaus Bartosch

" 1st Group (ASX:1ST) shares rise on Visionflex acquisition

Digital health company 1st Group (ASX:1ST) was up as much as 25 per cent on the…
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars

Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars